Resumen de New Injectable for Plaque Psoriasis

Diane S. Aschenbrenner

• * Secukinumab (Cosentyx) is a newly approved recombinant human monoclonal antibody used to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy (or both). Secukinumab is administered subcutaneously, either by the patient or a provider.

  * The most common adverse effects include diarrhea, nasopharyngitis, and upper respiratory infections. Those who receive secukinumab may also have severe allergic reactions and have an increased risk of developing infections.